 Rigel Pharmaceuticals, Inc. Nasdaq: RIGL today announced that Grifols S.A., its collaborative partner in Europe, has launched TAVLESSE in Germany and the United Kingdom. It was approved by the European Commission in January 2020 for the treatment of chronic immune thrombocytopenia ITP in adult patients who are refractory to other treatments. TAVLESSE, which is marketed in the U.S. under the brand name TAVALISSE, is an oral spleen tyrosine kinase SYK inhibitor that targets the underlying autoimmune cause of ITP by impeding platelet destruction. 